The current and future revolution in lung cancer screening and management
As guest editors, we are thrilled to present this specially curated issue of precision cancer medicine (PCM), wherein we have invited leading experts from around the globe to discuss currently evolving paradigms and controversies in the field of lung cancer.
Lung cancer has the highest mortality rate of all cancers. The time of diagnosis is directly translated to survival, with a high survival variability depending on the stage of the disease. Crucially, lung cancer screening with low-dose computed tomography (LDCT) showed a reduction in mortality by 26% in males and 40% in female compared to conventional chest radiography. Currently, most international guidelines recommend LDCT based screening for lung cancer among high-risk individuals.
The recent decade was rich with novel targeted therapies that increased the survival of NSCLC patients who harbor a driver mutation such as in EGFR, ALK or ROS1 gene. Later, immune checkpoint inhibitors (ICIs) has greatly impacted in those patients who do not harbor those mutations. ICIs became a landscape in first-line treatment in advanced NSCLC regardless of PD-L1 expression, as a single agent or in combination with chemotherapy. likewise, ICI became standard of care in stage III disease with an improved overall survival.
The current issue will explore the current recommendations in NSCLC, the mode of resistant to ICI, and further debates in targeted therapies, including of 1st line choice for EGFR and ALK arenas.
We thank and congratulate all the authors who graciously made the effort to generate these high-quality review papers for the scientific, and global community to learn from. We hope the readers will enjoy this edition of PCM as much as we did.
Acknowledgments
Funding: None.
Footnote
Provenance and Peer Review: This article was commissioned by the editorial office, Precision Cancer Medicine for the series dedicated to the Congress on Clinical Controversies in Lung Cancer (CCLC 2018). The article did not undergo external peer review.
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/pcm.2019.12.02). The series dedicated to the Congress on Clinical Controversies in Lung Cancer (CCLC 2018) was commissioned by the editorial office without any funding or sponsorship. NP served as the unpaid Guest Editor of the series and serves an unpaid editorial board member of Precision Cancer Medicine from Oct 2018 to Sep 2020. NP reports grants and personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, FoundationMedicine, Gaurdant360, Genesort, Merk, Merck Sharp & Dohme, Novartis, NovellusDx, Pfizer, Roche, Takeda. The authors have no other conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
Cite this article as: Kian W, Wallach N, Peled N. The current and future revolution in lung cancer screening and management. Precis Cancer Med 2020;3:1.
